Unknown PHASE2 INTERVENTIONAL 2-arm NCT02735317

Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT

Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT: A Single-center, Randomized Controlled Trial

Sponsor: Yun-fei Xia

Conditions Nasopharyngeal Neoplasms Stomatitis

Interventions Oral Ulcer Gargle (FORRAD®) Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine

Updated 7 times since 2017 Last updated: Apr 6, 2016 Started: Apr 30, 2016 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Nasopharyngeal Neoplasms and Stomatitis, this trial is ongoing. The trial is conducted by Yun-fei Xia and has accumulated 7 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
May 2018 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Feb 2017 — May 2018 [monthly]

Not Yet Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yun-fei Xia

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China